Arena Pharmaceuticals Announces the Presentation of Lorcaserin Hydrochloride Phase 2b Data at the 66th Annual Scientific Sessions of the American Diabetes Association

- Webcast Scheduled for June 13, 2006 -

SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Steven Smith, M.D., Principal Investigator, Associate Professor and Chief, In-Patient Unit of the Pennington Biomedical Research Center will present Phase 2b data on lorcaserin hydrochloride (formerly APD356) in an oral presentation at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) in Washington, D.C. on Monday, June 12, 2006.

Lorcaserin Phase 2b ADA Oral Presentation Details:

- Session Title: New Frontiers in "Diabesity" Treatment
- Date, Time & Location: June 12, 2006, 4:45 p.m.-5:00 p.m. Eastern Time (1:45 p.m. Pacific Time), Washington Convention Center, Room 145

Presenter: Steven Smith, M.D.

Phase 2b Data Review Webcast

The following morning, Tuesday, June 13, 2006, Arena will hold an Investor and Analyst Breakfast at the Four Points Sheraton Hotel in Washington, D.C. Dominic P. Behan, Ph.D., Senior Vice President and Chief Scientific Officer, William R. Shanahan, Jr., M.D., Vice President and Chief Medical Officer, and Steven Smith, M.D. will discuss the lorcaserin Phase 2b clinical results. The program will be webcast live, beginning at approximately 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time).

A live webcast of the June 13th presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focusing its research and development efforts on small molecule drugs in four major therapeutic areas: metabolic, central nervous system, cardiovascular and inflammatory diseases. Arena is developing a broad pipeline of compounds targeting an important class of drug targets called G protein-coupled receptors, or GPCRs, using its knowledge of GPCRs and its technologies, including CART™ and Melanophore. Arena has four internally discovered, clinical-stage drug candidates for major diseases. The most advanced, lorcaserin hydrochloride, is under investigation for the treatment of obesity. Arena's lead drug candidate for the treatment of insomnia, APD125, is a compound with a novel mechanism of action. Arena also has two clinical-stage collaborations with major pharmaceutical companies: Merck & Co., Inc. and Ortho-McNeil, Inc.

Contacts:
Jack Lief
President and CEO
Carolyn Wang
WeissComm Partners
Media Relations
415.946.1065
David Walsey
Director, Corporate Communications
Arena Pharmaceuticals, Inc.
858.453.7200, ext. 1682

SOURCE Arena Pharmaceuticals, Inc.